This really shouldn’t come as a surprise to anyone as another Diabetic Investor call has come true as Medtronic made it official this morning as Hooman Hakami is out and Sean Salmon is in as the new leader of the struggling diabetes unit. While this move took longer than we had anticipated we knew it was a done deal and are not surprised one bit.
Here is the official notice from the evil empire;
“Medtronic plc (NYSE:MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH) within the Cardiac and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.